1
|
Yang S, Jun M, Hong-Li Z, Jian-Min W, Chun W, Lu-Gui Q, Yong-Qiang Z, Jun Z, Jian H, Zhi-Xiang S. A multi-center open-labeled study of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma, or chronic lymphocytic leukemia in Chinese population. Int J Hematol 2008; 88:139-144. [PMID: 18629603 DOI: 10.1007/s12185-008-0130-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2008] [Revised: 05/30/2008] [Accepted: 06/16/2008] [Indexed: 10/21/2022]
Abstract
The purpose of this study is to investigate the efficacy and safety of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma (MM), low-grade non-Hodgkin's lymphoma (NHL), and chronic lymphocytic leukemia (CLL). From December 2005 to November 2006, the patients with MM, low-grade NHL, and CLL were enrolled in this study, male or female, aged > or = 18 years, transfusion-dependant, and receiving anti-neoplasia chemotherapy. Recombinant human erythropoietin-beta was used in this study with the dose initiated at 150 IU/kg, thrice a week, subcutaneously. The total treatment duration was 12 weeks. The primary endpoint of the study is response rate (RR), which is defined as hemoglobin increasing > or = 2 g/dL comparing to baseline level, or returning to normal range, without any transfusion within 6 weeks of evaluation. Fifty out of 82 (64.6%) patients enrolled in this study responded to the treatment and 29 patients had no response. Hypertension (12.2%) is the most common adverse effect; however, all the adverse events were mild, categorized in NCI grade I or II. We conclude that recombinant erythropoietin-beta was effective in the treatment of anemia of the patients with MM, NHL, and CLL, as well as it is well-tolerated.
Collapse
Affiliation(s)
- Shen Yang
- Department of Hematology, Ruijin Hospital, Shanghai JiaoTong University, School of Medicine, No.197 Ruijin Road II, Shanghai, 200025, China.
| | - Ma Jun
- Department of Hematology, Harbin Institute of Hematology, Harbin, China
| | - Zhu Hong-Li
- Department of Hematology, Chinese PLA General Hospital, Beijing, China
| | - Wang Jian-Min
- Department of Hematology, Changhai Hospital, Shanghai Second Military Medical University, Shanghai, China
| | - Wang Chun
- Department of Hematology, Shanghai First People's Hospital, Shanghai JiaoTong University, Shanghai, China
| | - Qiu Lu-Gui
- Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Zhao Yong-Qiang
- Department of Hematology, Peking Union Medical College Hospital, Beijing, China
| | - Zhu Jun
- Beijing Cancer Hospital, Beijing, China
| | - Hou Jian
- Department of Hematology Changzheng Hospital, Shanghai Second Military Medical University, Shanghai, China
| | - Shen Zhi-Xiang
- Department of Hematology, Ruijin Hospital, Shanghai JiaoTong University, School of Medicine, No.197 Ruijin Road II, Shanghai, 200025, China
| |
Collapse
|